Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.70 |
| ▸ | PPARA | Q07869 | 9/20 | 0.70 |
| ▸ | PPARG | P37231 | 6/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221307 | 0.93 | PPARD (0.60) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL5859790 | 0.93 | PPARD (0.72) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6218546 | 0.92 | PPARD (0.59) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6221740 | 0.90 | PPARD (0.57) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6221231 | 0.90 | PPARD (0.66) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6220873 | 0.89 | PPARD (0.54) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6221679 | 0.89 | PPARD (0.55) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6223674 | 0.87 | PPARD (0.54) | PPARDPPARAPPARGFFAR1 | |
| SCHEMBL6624441 | 0.86 | PPARD (0.62) | PPARDPPARAPPARGFFAR1CHRM5 | |
| SCHEMBL6052592 | 0.85 | PPARD (0.61) | PPARDPPARAPPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480641-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2004-12-01 | — | — | EP | claimed |
| WO-2003074051-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (GB) | 2003-09-12 | — | — | WO | claimed |
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | KALYPSYS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1480641-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074051-A1 | SUBSTITUTED THIAZOLES AND OXAZOLES THAT MODULATE PPAR ACTIVITY | WARNER-LAMBERT COMPANY LLC (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203151-A1 | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions | PPARG, PPARD, PPARA | PPARD 2/4885PPARA 3/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.